医疗器械公司AngioDynamics已采取法律行动，于2026年4月23日正式向Endovascular Engineering公司提起专利侵权诉讼。根据提交给美国证券交易委员会（SEC）的文件，此次诉讼指控后者侵犯了其持有的特定专利。
该法律文件的提交标志着两家公司在医疗器械领域的知识产权纠纷进入新阶段。专利侵权指控通常涉及复杂的技术细节和法律论证，后续进展将对相关企业的业务运营产生潜在影响。
医疗器械公司AngioDynamics已采取法律行动，于2026年4月23日正式向Endovascular Engineering公司提起专利侵权诉讼。根据提交给美国证券交易委员会（SEC）的文件，此次诉讼指控后者侵犯了其持有的特定专利。
该法律文件的提交标志着两家公司在医疗器械领域的知识产权纠纷进入新阶段。专利侵权指控通常涉及复杂的技术细节和法律论证，后续进展将对相关企业的业务运营产生潜在影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.